AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 4 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Two different vaccine vehicles carrying the same anti-tumor gene show significant differences in potency, according to a report published in Gene Therapy.
"We hypothesized that different delivery systems may influence the pattern of antigen-specific immune response and the outcome of anti-tumor effect," said C.H. Chen and colleagues. "We therefore evaluated recombinant vaccinia virus and naked DNA for the generation of antigen-specific immune responses and anti-tumor effects."
Chen and team used recombinant vaccinia and naked DNA vaccines containing the chimeric Sig/E7/LAMP-1 gene to control the growth of human papillomavirus (HPV) 16 E7-expressing tumor cells (TC-1) in mice.
The naked DNA vaccine offered 100% protection from subcutaneous tumor growth while the vaccinia vaccine protected only 40% of mice, noted Chen. The DNA vaccine also was able to subdue tumors generated from a subclone of TC-1 that survived the vaccinia vaccination.
Further analysis with immunological assay showed that the vaccinia vaccine induced secretion of interleukin-4 (IL-4) while the naked DNA vaccine did not ("Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the ...
Source: HighBeam Research, Naked DNA Vaccines Offer Better Anti-Tumor Potency Than Vaccinia...